Artificial intelligence in glioma imaging: challenges and advances

Weina Jin, Mostafa Fatehi, Kumar Abhishek, Mayur Mallya, Brian Toyota, Ghassan Hamarneh

Abstract

Primary brain tumors including gliomas continue to pose significant management challenges to clinicians. While the presentation, the pathology, and the clinical course of these lesions are variable, the initial investigations are usually similar. Patients who are suspected to have a brain tumor will be assessed with computed tomography (CT) and magnetic resonance imaging (MRI). The imaging findings are used by neurosurgeons to determine the feasibility of surgical resection and plan such an undertaking. Imaging studies are also an indispensable tool in tracking tumor progression or its response to treatment. As these imaging studies are non-invasive, relatively cheap and accessible to patients, there have been many efforts over the past two decades to increase the amount of clinically-relevant information that can be extracted from brain imaging. Most recently, artificial intelligence (AI) techniques have been employed to segment and characterize brain tumors, as well as to detect progression or treatment-response. However, the clinical utility of such endeavours remains limited due to challenges in data collection and annotation, model training, and the reliability of AI-generated information. We provide a review of recent advances in addressing the above challenges. First, to overcome the challenge of data paucity, different image imputation and synthesis techniques along with annotation collection efforts are summarized. Next, various training strategies are presented to meet multiple desiderata, such as model performance, generalization ability, data privacy protection, and learning with sparse annotations. Finally, standardized performance evaluation and model interpretability methods have been reviewed. We believe that these technical approaches will facilitate the development of a fully-functional AI tool in the clinical care of patients with gliomas.

Introduction

Gliomas represent the most common and aggressive primary brain tumors, necessitating precise neuroimaging for diagnosis, surgical planning, and longitudinal monitoring. While Artificial Intelligence (AI) has demonstrated significant potential in automating these tasks, a substantial "clinical utility gap" persists. High performance in a research environment does not inherently translate to clinical readiness. This review identifies three critical bottlenecks preventing the transition of experimental algorithms into functional clinical decision support systems: data scarcity, model training complexities, and the "black box" nature of deep learning.

Overview of the primary challenges in AI glioma imaging and the technical approaches proposed to bridge the clinical utility gap.

Addressing the Data and Training Bottleneck

Data & Annotation Scarcity

Medical imaging data is inherently difficult to aggregate due to high acquisition costs, stringent privacy regulations, and the requirement for time-intensive expert labeling. To mitigate this, researchers are increasingly employing Generative Adversarial Networks (GANs) to synthesize entirely new training data or "fill in" missing MRI sequences. This synthetic data has reached a level of realism where radiologists often struggle to distinguish it from real patient scans in "Visual Turing Tests."

Privacy-Preserving and Weakly Supervised Training

To address privacy concerns, Federated Learning has emerged as a decentralized alternative to traditional data sharing. In this framework, models are trained locally at individual hospitals, and only model parameters—rather than raw patient data—are shared centrally. Evidence suggests that Federated Learning can achieve performance nearly identical to centralized datasets (e.g., a Dice score of 0.852 vs. 0.862). Furthermore, semi-supervised and unsupervised techniques are being developed to allow models to learn from "weak" labels, such as image-level tags or bounding boxes, rather than requiring pixel-perfect manual segmentations.

Key Insights and Results

Molecular Classification and Segmentation

State-of-the-art architectures, such as 3D U-Net and Densely Connected CNNs, are achieving high accuracy on benchmark datasets like BraTS. Beyond simple segmentation, deep models (e.g., VGG16, ResNet) are now capable of predicting critical molecular markers directly from non-invasive imaging. This includes identifying IDH mutation status and 1p/19q co-deletion, tasks that traditionally required invasive surgical biopsies.

MRI presentation of different glioma subtypes, illustrating the molecular markers (IDH and 1p/19q status) that AI models are now trained to predict non-invasively.

Explainable AI (XAI)

To overcome the trust deficit among clinicians, the field is moving toward "Explainable AI." These methods categorize how a model reaches a decision through various lenses:

  • Activation-based: Visualizing what features the network identifies.
  • Gradient-based: Highlighting specific pixels that influenced the final output.
  • Perturbation-based: Testing how modifications to the input image alter the model's prediction.

Limitations and Future Outlook

Despite these advances, several challenges remain. Current interpretability methods lack standardized metrics, making it difficult to quantify if an explanation truly aids clinical decision-making. Furthermore, models often suffer from "domain shift," where performance drops when applied to data from different hospital scanners.

Future development must move beyond pure algorithmic accuracy toward a 4-Phase Evaluation Framework, similar to pharmaceutical clinical trials. This includes moving from laboratory validation (Phase I) to randomized controlled trials in clinical settings (Phase III). Ultimately, the success of AI in neuro-oncology depends on seamless integration into the existing workflows of neurosurgeons and radiologists, emphasizing human-in-the-loop systems and user-centric design.

Summary updated

Abstract

Primary brain tumors including gliomas continue to pose significant management challenges to clinicians. While the presentation, the pathology, and the clinical course of these lesions are variable, the initial investigations are usually similar. Patients who are suspected to have a brain tumor will be assessed with computed tomography (CT) and magnetic resonance imaging (MRI). The imaging findings are used by neurosurgeons to determine the feasibility of surgical resection and plan such an undertaking. Imaging studies are also an indispensable tool in tracking tumor progression or its response to treatment. As these imaging studies are non-invasive, relatively cheap and accessible to patients, there have been many efforts over the past two decades to increase the amount of clinically-relevant information that can be extracted from brain imaging. Most recently, artificial intelligence (AI) techniques have been employed to segment and characterize brain tumors, as well as to detect progression or treatment-response. However, the clinical utility of such endeavours remains limited due to challenges in data collection and annotation, model training, and the reliability of AI-generated information. We provide a review of recent advances in addressing the above challenges. First, to overcome the challenge of data paucity, different image imputation and synthesis techniques along with annotation collection efforts are summarized. Next, various training strategies are presented to meet multiple desiderata, such as model performance, generalization ability, data privacy protection, and learning with sparse annotations. Finally, standardized performance evaluation and model interpretability methods have been reviewed. We believe that these technical approaches will facilitate the development of a fully-functional AI tool in the clinical care of patients with gliomas.
BibTeX
@article{jin2020artificial,
  author = {Weina Jin and Mostafa Fatehi and Kumar Abhishek and Mayur Mallya and Brian Toyota and Ghassan Hamarneh},
  title = {{Artificial intelligence in glioma imaging: challenges and advances}},
  journal = {Journal of Neural Engineering},
  year = {2020},
  doi = {10.1088/1741-2552/ab8131},
}
Figure